Drugs / MST-0312
last change Apr 2026 re-read 2 minutes ago

MST-0312

Developed for
cancer
Investigated by
Mestag Therapeutics Limited

Trials 1 · a red edge is where a trial was stopped

2027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07610941 Apr 2026 → Dec 2029 expected cancer Mestag Therapeutics Limited Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MST-0312 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07610941